Effect on BMI of GnRH Analogue Treatment in CPP or EFP Girls

CHEN Qiu-li, SU Zhe, LI Yan-hong, MA Hua—mei, CHEN Hong-shan, ZHANG Jun, DU Min-lian

Objective:
We assessed in a retrospective unicenter study the effect on BMI of treatment with GnRH analogs (GnRHAs) in central precocious puberty (CPP) or early and fast puberty (EFP) girls.

Methods:
The BMI of 318 girls (227 CPP and 91 EFP) who treated with GnRHAs alone were analyzed. Among them 89 were followed up to their final adult height (FAH).

Results:
Before GnRH treatment started, the girls with CPP and EFP had a mean BMI SDS for chronological age (CA) of 0.39±0.84 and for bone age (BA) of −0.11±0.69. At the end of treatment, the mean BMI SDS was 0.59±1.00 for CA and 0.24±0.85 for BA, which both were significantly higher than initiation. The increment of BMI SDS for BA (0.38±0.56) was larger than for CA (0.21±0.59). Moreover, the ratio of overweight (BMI >85%) was significantly elevated. BMI SDS for CA of 89 girls who were visited at their FAH were 0.17±1.73, which were similar with BMI SDS at initiation and normal population.

Conclusion:
The mean BMI SDS for CA of CPP and EFP was significantly higher than population, while for BA was significantly lower. During GnRHAs treatment, there was an obese tendency and which was reversible. At FAH, the mean BMI SDS was back to normal.

Table 1 Parameters when start and withdraw treatment of GnRHAs

<table>
<thead>
<tr>
<th>GnRH treatment</th>
<th>case</th>
<th>Age</th>
<th>BA</th>
<th>BMI</th>
<th>BMI SDS for age</th>
<th>BMI SDS for BA</th>
</tr>
</thead>
<tbody>
<tr>
<td>start</td>
<td>318</td>
<td>8.6±1.3</td>
<td>10.7±1.2</td>
<td>16.5±1.9</td>
<td>0.38±0.84a</td>
<td>-0.11±0.69a</td>
</tr>
<tr>
<td>withdraw</td>
<td>318</td>
<td>10.8±1.1</td>
<td>11.8±0.9</td>
<td>18.1±2.5</td>
<td>0.59±1.01ab</td>
<td>0.24±0.89ab</td>
</tr>
</tbody>
</table>

a: compare with normal population $P<0.01$; b: withdraw vs start. $P<0.001$. 

*compare with last time $P<0.05$